Lessons from the HEALEY adaptive platform trial in amyotrophic lateral sclerosis

Abstract

Platform trials present potential advantages over stand-alone clinical trials. Here, we describe the operational framework of the HEALEY Amyotrophic Lateral Sclerosis Platform Trial, which enables an adaptable operational infrastructure, concurrent enrolment into four distinct regimens and an accelerated start-up time for a new regimen added after initial trial launch.